Cargando…
Prognostic value of low muscle mass at the 12(th) thoracic vertebral level in multiple myeloma treated with transplantation: CAREMM-2101 study
PURPOSE: Autologous hematopoietic stem cell transplantation (ASCT) has been introduced as a standard treatment for newly diagnosed multiple myeloma (NDMM) following novel agent-based induction chemotherapy. This study investigated whether pre-ASCT low muscle mass evaluated using the paraspinal muscl...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Galenos Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679641/ https://www.ncbi.nlm.nih.gov/pubmed/37312491 http://dx.doi.org/10.4274/dir.2023.232097 |
_version_ | 1785150618056261632 |
---|---|
author | Park, Sung-Soo Kwag, Daehun Lee, Jung Yeon Jeon, Young-Woo Yahng, Seung-Ah Shin, Seung-Hwan Youn, Seo Yeon Min, Chang-Ki |
author_facet | Park, Sung-Soo Kwag, Daehun Lee, Jung Yeon Jeon, Young-Woo Yahng, Seung-Ah Shin, Seung-Hwan Youn, Seo Yeon Min, Chang-Ki |
author_sort | Park, Sung-Soo |
collection | PubMed |
description | PURPOSE: Autologous hematopoietic stem cell transplantation (ASCT) has been introduced as a standard treatment for newly diagnosed multiple myeloma (NDMM) following novel agent-based induction chemotherapy. This study investigated whether pre-ASCT low muscle mass evaluated using the paraspinal muscle index (PMI) at the 12(th) thoracic vertebra (T12) level is a reliable prognostic marker in NDMM after chemotherapy. METHODS: A multi-center registry database was retrospectively analyzed. Between 2009 and 2020, 190 patients with chest computed tomography images underwent frontline ASCT following induction therapy. The PMI was defined as the value of the paraspinal muscle area at the T12 level divided by the square of the patient’s height. The cut-off value indicating a low muscle mass was sex-specific, using the lowest quintiles. RESULTS: Of the 190 patients, 38 (20%) were in the low muscle mass group. The low muscle mass group had a lower 4-year overall survival (OS) rate than the non-low muscle mass group (68.5% vs. 81.2%; P = 0.074). The median progression-free survival (PFS) in the low muscle mass group was significantly shorter compared with the non-low muscle mass group (23.3 months vs. 29.2 months; P = 0.029). The cumulative incidence of transplant-related mortality (TRM) was significantly higher in the low muscle mass group than in the non-low muscle mass group (4-year probability of TRM incidence, 10.6% vs. 0.7%; P < 0.001). In contrast, no significant difference in the cumulative incidence of disease progression was found between the two groups. Multivariate analysis revealed that low muscle mass was associated with significant negative outcomes for OS [(hazard ratio (HR): 2.14; P = 0.047], PFS (HR: 1.78; P = 0.012), and TRM (HR: 12.05; P = 0.025). CONCLUSION: Paraspinal muscle mass may have a prognostic role in NDMM patients who undergo ASCT. Patients with low paraspinal muscle mass have lower survival outcomes compared to non-low muscle mass group. |
format | Online Article Text |
id | pubmed-10679641 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Galenos Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-106796412023-12-05 Prognostic value of low muscle mass at the 12(th) thoracic vertebral level in multiple myeloma treated with transplantation: CAREMM-2101 study Park, Sung-Soo Kwag, Daehun Lee, Jung Yeon Jeon, Young-Woo Yahng, Seung-Ah Shin, Seung-Hwan Youn, Seo Yeon Min, Chang-Ki Diagn Interv Radiol General Radiology - Original Article PURPOSE: Autologous hematopoietic stem cell transplantation (ASCT) has been introduced as a standard treatment for newly diagnosed multiple myeloma (NDMM) following novel agent-based induction chemotherapy. This study investigated whether pre-ASCT low muscle mass evaluated using the paraspinal muscle index (PMI) at the 12(th) thoracic vertebra (T12) level is a reliable prognostic marker in NDMM after chemotherapy. METHODS: A multi-center registry database was retrospectively analyzed. Between 2009 and 2020, 190 patients with chest computed tomography images underwent frontline ASCT following induction therapy. The PMI was defined as the value of the paraspinal muscle area at the T12 level divided by the square of the patient’s height. The cut-off value indicating a low muscle mass was sex-specific, using the lowest quintiles. RESULTS: Of the 190 patients, 38 (20%) were in the low muscle mass group. The low muscle mass group had a lower 4-year overall survival (OS) rate than the non-low muscle mass group (68.5% vs. 81.2%; P = 0.074). The median progression-free survival (PFS) in the low muscle mass group was significantly shorter compared with the non-low muscle mass group (23.3 months vs. 29.2 months; P = 0.029). The cumulative incidence of transplant-related mortality (TRM) was significantly higher in the low muscle mass group than in the non-low muscle mass group (4-year probability of TRM incidence, 10.6% vs. 0.7%; P < 0.001). In contrast, no significant difference in the cumulative incidence of disease progression was found between the two groups. Multivariate analysis revealed that low muscle mass was associated with significant negative outcomes for OS [(hazard ratio (HR): 2.14; P = 0.047], PFS (HR: 1.78; P = 0.012), and TRM (HR: 12.05; P = 0.025). CONCLUSION: Paraspinal muscle mass may have a prognostic role in NDMM patients who undergo ASCT. Patients with low paraspinal muscle mass have lower survival outcomes compared to non-low muscle mass group. Galenos Publishing 2023-07-20 /pmc/articles/PMC10679641/ /pubmed/37312491 http://dx.doi.org/10.4274/dir.2023.232097 Text en © Copyright 2023 by Turkish Society of Radiology | Diagnostic and Interventional Radiology, published by Galenos Publishing House. https://creativecommons.org/licenses/by-nc/4.0/Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. (https://creativecommons.org/licenses/by-nc/4.0/) |
spellingShingle | General Radiology - Original Article Park, Sung-Soo Kwag, Daehun Lee, Jung Yeon Jeon, Young-Woo Yahng, Seung-Ah Shin, Seung-Hwan Youn, Seo Yeon Min, Chang-Ki Prognostic value of low muscle mass at the 12(th) thoracic vertebral level in multiple myeloma treated with transplantation: CAREMM-2101 study |
title | Prognostic value of low muscle mass at the 12(th) thoracic vertebral level in multiple myeloma treated with transplantation: CAREMM-2101 study |
title_full | Prognostic value of low muscle mass at the 12(th) thoracic vertebral level in multiple myeloma treated with transplantation: CAREMM-2101 study |
title_fullStr | Prognostic value of low muscle mass at the 12(th) thoracic vertebral level in multiple myeloma treated with transplantation: CAREMM-2101 study |
title_full_unstemmed | Prognostic value of low muscle mass at the 12(th) thoracic vertebral level in multiple myeloma treated with transplantation: CAREMM-2101 study |
title_short | Prognostic value of low muscle mass at the 12(th) thoracic vertebral level in multiple myeloma treated with transplantation: CAREMM-2101 study |
title_sort | prognostic value of low muscle mass at the 12(th) thoracic vertebral level in multiple myeloma treated with transplantation: caremm-2101 study |
topic | General Radiology - Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679641/ https://www.ncbi.nlm.nih.gov/pubmed/37312491 http://dx.doi.org/10.4274/dir.2023.232097 |
work_keys_str_mv | AT parksungsoo prognosticvalueoflowmusclemassatthe12ththoracicvertebrallevelinmultiplemyelomatreatedwithtransplantationcaremm2101study AT kwagdaehun prognosticvalueoflowmusclemassatthe12ththoracicvertebrallevelinmultiplemyelomatreatedwithtransplantationcaremm2101study AT leejungyeon prognosticvalueoflowmusclemassatthe12ththoracicvertebrallevelinmultiplemyelomatreatedwithtransplantationcaremm2101study AT jeonyoungwoo prognosticvalueoflowmusclemassatthe12ththoracicvertebrallevelinmultiplemyelomatreatedwithtransplantationcaremm2101study AT yahngseungah prognosticvalueoflowmusclemassatthe12ththoracicvertebrallevelinmultiplemyelomatreatedwithtransplantationcaremm2101study AT shinseunghwan prognosticvalueoflowmusclemassatthe12ththoracicvertebrallevelinmultiplemyelomatreatedwithtransplantationcaremm2101study AT younseoyeon prognosticvalueoflowmusclemassatthe12ththoracicvertebrallevelinmultiplemyelomatreatedwithtransplantationcaremm2101study AT minchangki prognosticvalueoflowmusclemassatthe12ththoracicvertebrallevelinmultiplemyelomatreatedwithtransplantationcaremm2101study |